Prognostic factors and causes of death in Korean patients with idiopathic pulmonary fibrosis  by Jeon, Kyeongman et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 451–457KEYWORD
Interstitial
disease;
Pulmonary
Survival;
Cause of d
0954-6111/$ - s
doi:10.1016/j.r
Correspondi
E-mail addrPrognostic factors and causes of death in Korean
patients with idiopathic pulmonary fibrosis
Kyeongman Jeona, Man Pyo Chunga,, Kyung Soo Leeb, Myung Jin Chungb,
Joungho Hanc, Won-Jung Koha, Gee Young Suha, Hojoong Kima, O
Jung KwonaaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Kangnam-ku, Seoul 135-710, South Korea
bDepartment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine,
50 Ilwon-dong, Kangnam-ku, Seoul 135-710, South Korea
cDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine,
50 Ilwon-dong, Kangnam-ku, Seoul 135-710, South Korea
Received 23 December 2004; accepted 16 June 2005S
lung
fibrosis;
eath
ee front matter & 2005
med.2005.06.013
ng author. Tel.: +82 2 3
ess: mpchung@smc.samSummary The purpose of this study was to investigate the prognostic factors at
initial presentation and the causes of death in Korean patients with idiopathic
pulmonary fibrosis (IPF), which might be different report wise, in comparison to the
western countries. A retrospective review of 88 patients (mean 60.3 years, 69 male)
was carried out and they were diagnosed as IPF positive. After diagnosis, the survival
rate was 57% and 41% for third and fifth year, respectively (mean follow-up 39.1
months). Mortality was closely correlated with severe dyspnea at presentation
(Hazard Ratio [HR], 2.6 per grade; p ¼ 0:015), lower initial forced vital capacity (HR,
1.7 per 10% predicted; p ¼ 0:004) and lower initial diffusing capacity of the lung (HR,
1.5 per 10% predicted; p ¼ 0:033). Treatment with specific drugs was ineffective
against the survival when compared with symptomatic supportive care. Thirty-four
patients (68%) died of worsened respiratory failure, seven (14%) died of infection and
only one patient showed cardiovascular death. In conclusion, our study suggests that
the severity of dyspnea and lung function tests at the time of diagnosis are the
predictive factors for the survival of patients with IPF. In comparison to the reports
from western countries, we observed that respiratory failure and pulmonary
infection were more frequent causes of death, while cardiovascular death was rare
in Korean patients with IPF.
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Idiopathic pulmonary fibrosis (IPF) is a chronic
interstitial lung disease (ILD) of unknown etiology
and is characterized by progressive lung fibrosis and
eventually fatal clinical outcome.1–5 As good
response to current therapeutic agents, such as
corticosteroids or cytotoxic agents, is unusual,
medical treatment is unlikely to alter clinical
course in most of the patients.6–8 Therefore, the
median survival of IPF patients is found to be less
than five years after diagnosis.9–14 Although earlier
studies have identified a number of factors that
seem to affect the survival, like old age,7 patient’s
gender,7,15 poor pulmonary function tests at diag-
nosis,7,12 cigarette smoking status,12,15 higher
degree of dyspnea at presentation,12 higher extent
of honeycombing on high-resolution computed
tomography (HRCT) scan11 and poor response to
initial steroid therapy,8 the prognosis of an indivi-
dual patient is still an intricate task.
The progression of lung fibrosis is the most
common cause of respiratory failure in IPF upon
deterioration.16–19 In 1990, Panos et al.19 reported
that most of the patients with IPF died of
respiratory failure, and cardiovascular disease,
bronchogenic carcinoma and infection were also
other common causes of death in the western
countries. Unfortunately, other causes of clinical
deterioration, such as heart failure, pulmonary
embolism or pneumonia are often difficult to be
distinguished from acute exacerbation of IPF.19,20
As the mortality due to cardiovascular diseases is
low in Asian-Pacific region,21 we hypothesized that
the prognostic factors at initial presentation and
causes of death in the Asian patients with IPF might
be different from those reported in the western
countries. In the present study, we retrospectively
investigated the clinical outcome of IPF to find out
the prognostic factors at diagnosis and the causes
of death in Korean patients with IPF.Materials and methods
Patients
Eighty-eight patients were included in the present
retrospective study. Between July 1996 and June
2002, 61 patients (69%) were pathologically con-
firmed to have usual interstitial pneumonia (UIP) on
surgical lung biopsy, while 27 patients were
diagnosed as IPF positive by clinical diagnostic
criteria of American Thoracic Society (ATS).1 Since
our hospital is a tertiary referral medical center,patients were referred to ILD clinic of our hospital
from all over the country. Patients were excluded
from the study if there were clinical evidence of
connective tissue disease, occupational or environ-
mental exposure, or a history of ingestion of a drug
known to cause interstitial lung disease. Among the
patients without undergoing surgical lung biopsy,
those showing no honeycombing on HRCTwere also
excluded to preclude non-UIP from being in-
cluded.22 Surgical lung biopsy was performed by
either open thoracotomy or video-assisted thoraco-
scopy. Pathological specimens of the lung were
independently reviewed by three lung pathologists
(J. Han, Samsung Medical Center; M. Kitaichi, Kyoto
University and T.V. Colby, Mayo Clinic Scottsdale)
who were familiar with the characteristic histolo-
gical features of idiopathic interstitial pneumonia.
Histological diagnosis of UIP was carried out after
the pathologists agreed to it. All the patients were
followed up for more than a year after diagnosis.Data collection
The medical records were retrospectively reviewed
for gathering information. Patient’s age at diag-
nosis, sex, smoking history, symptoms and signs at
presentation, laboratory tests, pulmonary function
tests, medical treatment, and final clinical out-
come were also ascertained. The date of surgical
lung biopsy or diagnosis of IPF by clinical diagnostic
criteria was recorded as the date of diagnosis. Date
and causes of death were identified from medical
records, by interviewing the patients’ family or
doctors, or by search of the national death registry.
When lung lesion deteriorated rapidly, meticulous
work-up for its etiologies, such as chest CT, cardiac
echo, serology for atypical agents, and all available
cultures for bacteria, virus, acid-fast bacilli and
fungus including culture of bronchoalveolar lavage
(BAL) fluid were carried out for the diagnosis of
infectious pneumonia, heart failure, pulmonary
embolism, etc. Pneumonia was diagnosed clinically
by the presence of radiographic appearance of new
infiltrates, fever, leukocytosis, and purulent spu-
tum. When both pneumonia and acute exacerba-
tion of IPF were clinically suspected, it was our
practice to investigate the potential etiologic
organisms extensively. Blood and sputum cultures,
and serologic tests for Legionella pneumophila,
Mycoplasma pneumoniae and Chlamydia pneumo-
niae were performed. BAL was done with stains and
cultures of BAL fluid for bacterial organisms, acid-
fast bacilli, Pneumocystis carinii, and viruses such
as respiratory syncytial virus (RSV), adenovirus,
influenza virus, parainfluenza virus, herpes simplex
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virus (CMV).
Spirometry, plethysmographic lung volumes and
single-breath carbon monoxide diffusing capacity
of the lungs (DLco) were obtained within 2 weeks at
the time of diagnosis with pulmonary function units
(SensorMedics Corporation, Yorba Linda, CA).
Forced vital capacity (FVC) and forced expiratory
volume in 1 s (FEV1) were measured as recom-
mended by the ATS.23 Reference value by Morris
et al.24 was used to define the predicted values for
the spirometric data. Plethysmographic measure-
ment of total lung capacity (TLC) was performed as
recommended.25 With the usage of 10 s single-
breath-hold technique of Burrows et al.,26 the
percentage predicted value for DLco was also
determined.
Chest HRCT was performed with a HiSpeed
Advantage Scanner (General Electric Medical Sys-
tem, Milwaukee, WI). HRCTscans of the thorax with
1mm collimation at 10mm intervals were ob-
tained, as described previously.27 Two chest radi-
ologists (KS Lee and MJ Chung) reviewed the CT
images mutually and simultaneously, and the
decisions on the findings were reached by a
consensus. The observers assessed the presence
and extent of areas of ground glass attenuation,
irregular linear opacity and honeycombing, the
extent was scored to the nearest 5%. When less
than 10% of the lung was involved, an estimate to
the nearest 1% was recorded.
Bronchoscopy with BAL was carried out at the
time of diagnosis of IPF. This was done using
the standard techniques as previously described.23
The percentages of lymphocytes, neutrophils and
eosinophils in BAL fluid were determined on
cytocentrifuged slides using standard criteria.28Data analysis
The SPSS Win 11.5.0 statistical package was used
for data analysis. Unless indicated otherwise, data
were presented as mean71 standard deviation (SD)
for continuous variables and as percentages for
discrete variables. Baseline clinical characteristics
were compared using t-test for continuous vari-
ables and chi-square (w2) test for discrete variables.
For survival analysis, time zero was defined as the
date of diagnosis of IPF as mentioned before.
Cumulative survival probabilities were estimated
using the Kaplan–Meier method and the log-rank
test was used to compare the survival of different
groups. Cox proportional hazards regression was
used to identify variables associated with survival
rate. Hazard ratios were reported for theseanalyses. All the reported P values were two-
tailed, and a value of less than 0.05 was considered
significant.Results
There were 69 male and 19 female patients with a
mean age of 60.377.5 years (Table 1). Thirty
patients (34%) were non-smokers. Most of the
patients (n ¼ 78, 89%) complained of exertional
dyspnea with mean duration of 6.8 months (range,
0–72 months; 95% confidence interval [CI], 3.9–9.6)
prior to surgical lung biopsy or diagnosis of IPF by
clinical diagnostic criteria. Upon diagnosis, mean
FVC and DLco were 74.0719.2% and 65.2721.4%
(predicted value), respectively. No appreciable
difference in clinical characteristics upon diagnosis
was found between the patients diagnosed by ATS
diagnostic criteria and those with surgical lung
biopsy, except for old age in the former case (mean
64.4 years versus 58.5 years, po0:001). Forty-nine
patients (56%) received specific treatment with
cyclophosphamide (n ¼ 25, 28%), corticosteroids
(n ¼ 15, 17%), interferon-gamma (n ¼ 3, 3%),
azathioprine (n ¼ 1, 1%) or more than one drug
(n ¼ 5, 6%). The remaining 39 patients (44%) were
managed with symptomatic supportive care only.
The decision whether to give specific treatment or
symptomatic supportive care was made by indivi-
dual clinician on the basis of respiratory symptoms,
disease activity, patients’ intention and age.
Except for old age in the symptomatic supportive
care group (po0:05), there was no difference in
clinical profile between the specific treatment
group and the symptomatic supportive care group.
The mean follow-up duration was 39.1 months
(range, 2–117 months; 95% CI, 33.5–44.6). Out of 88
patients, 50 patients (57%) were found to be
deceased. The median survival was found to be 46
months (95% CI, 29–63) (Fig. 1). The survival rate
for the third and fifth year was 57% and 41%,
respectively. The survival rate was not different
between the specific treatment group (55 months;
95% CI, 34–76) and the symptomatic supportive
care group (34 months; 95% CI, 21–47) (p ¼ 0:185)
(Fig. 2).
In univariate analysis, mortality was associated
with severe dyspnea (p ¼ 0:002), presence of finger
clubbing (p ¼ 0:039), lower FVC (po0:001), lower
TLC (po0:001), lower DLco (po0:001), and higher
extent of irregular linear opacity (po0:001) and
honeycombing (po0:001) on HRCT. In multivariate
analysis, however, mortality was found to be corre-
lated only with severe dyspnea at presentation
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Figure 1 Kaplan-Meier plot of survival probability from
the time of the diagnosis of IPF in all the patients
(n ¼ 88).
Table 1 Baseline clinical characteristics of 88 subjects.
Characteristics All patients
(n ¼ 88)
Specific
treatment group
(n ¼ 49)
Symptomatic
supportive care
group (n ¼ 39)
p value
Age, mean7SD years 60.377.5 58.977.1 62.177.8 0.047
Sex, male:female 69:19 39:10 30:9 0.799
Smoking, never:former:current 30:33:25 14:22:13 16:11:12 0.254
Dyspnea scale, Gr0:Gr1:Gr2:Gr3:Gr4 10:16:45:16:1 3:7:30:9:0 7:9:15:7:1 0.364
Finger clubbing, yes:no 32:56 21:28 11:28 0.185
Exacerbation history, yes:no 14:74 10:39 4:35 0.248
PFT
FVC, mean7SD % pred 74.0719.2 74.6718.1 73.2720.8 0.758
TLC, mean7SD % pred 76.7717.2 75.3715.7 78.9719.3 0.410
DLco, mean7SD % pred 65.2721.4 64.7720.5 65.8722.9 0.834
HRCT
Ground glass attenuation, mean7SD % 23.1717.7 21.9717.1 24.6718.5 0.490
Irregular linear opacity, mean7SD % 11.876.7 12..377.1 11.076.0 0.356
Honeycombing, mean7SD % 7.477.8 8.678.5 5.876.4 0.098
BAL fluid analysis
Neutrophil, mean7SD % 13.1712.3 11.4711.1 14.9713.3 0.233
Lymphocyte, mean7SD % 9.179.9 8.879.0 9.4710.9 0.775
Eosinophil, mean7SD % 1.572.7 2.073.5 1.071.0 0.125
Pathologic diagnosis:Clinical diagnosis 61:27 38:11 23:16 0.068
PFT, pulmonary function test; FVC, forced vital capacity; TLC, total lung capacity; DLco, diffusing capacity of the lung; HRCT,
high-resolution computed tomography; BAL, bronchoalveolar lavage.
Between specific treatment group and symptomatic supportive care group.
Figure 2 Kaplan–Meier plot of survival probability from
the time of the diagnosis of IPF stratified by the specific
treatment group (—, n ¼ 49) and the symptomatic
supportive care group (– – –, n ¼ 39).
K. Jeon et al.454(p ¼ 0:015), lower FVC (p ¼ 0:004) and lower DLco
(p ¼ 0:033) at diagnosis (Table 2). After taking into
account the age, sex, severity of dyspnea, FVC, and
DLco, there was no evidence to indicate that
improved survival was associated with the specific
treatment (p40:05).
Table 3 reports the causes of death in patients
with IPF. Thirty-four patients (68%) died of worsen-ing respiratory failure, and amongst them, 23
patients experienced acute exacerbation of IPF
while 11 showed slow progression of the disease.
Seven patients died of infection, with pneumonia as
a common cause. Lung cancer was the direct cause
of death in four patients. Pulmonary embolism,
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Table 2 Predictors of the mortality of IPF patients by multivariate analysis.
Characteristics HR 95% CI p value
Lower Upper
Dyspnea scale, grade (m) 2.6y 1.2 5.5 0.015
FVC, % predicted (k) 1.7z 1.2 2.3 0.004
DLco, % predicted (k) 1.5z 1.1 2.1 0.033
HR, hazard ratio; FVC, forced vital capacity; DLco, diffusing capacity of the lung.
p value associated with Wald test.
yPer grade increase.
zPer 10% point decrease.
Table 3 Causes of death in patients with IPF
(n ¼ 50).
Cause of death Number of patients (%)
Respiratory failure 34 (68%)
Acute exacerbation 23
Slow progression 11
Infection 7 (14%)
HAP 4
CAP 2
Wound infection 1
Lung cancer 4 (8%)
Pulmonary embolism 1 (2%)
Cardiovascular disease 1 (2%)
Variceal bleeding 1 (2%)
Unknown 2 (4%)
HAP, hospital-acquired pneumonia; CAP, community-ac-
quired pneumonia.
Survival of IPF in Korea 455cardiovascular disease and variceal bleeding were
the causes of death in three patients, respectively.
The obvious cause of death was not identified in the
remaining two patients.Discussion
The present retrospective study was carried out to
find the predictive factors for longer survival rate in
IPF patients and to investigate the causes of death
in Asian patients (with IPF). We observed that the
severity of dyspnea and lung function at initial
presentation were independent predictive factors
for survival of IPF patients, which are consistent
with the results by King et al.12 In the report by
Nagai et al.,29 it has not described whether these
factors had the prognostic value in Japanese
patients with IPF because only age and gender
were analyzed. In addition, our study suggestedthat the specific medical treatment did not
improve the survival of patients with IPF. This
finding supports the result of previous retrospective
studies which failed to document survival benefit
with any other form of therapy in IPF.1,2,7,30
In many studies on the clinical outcome in IPF,
their patients were required to have a surgical lung
biopsy to verify UIP.9,11–14,29 For that reason,
patients who were too ill or were considered at
high risk for postoperative complication after
general anesthesia, or refused the surgical lung
biopsy, might not be included for investigation.
Surgical lung biopsy is not always necessary for the
diagnosis of IPF.1 In an epidemiologic study, only
11% of patients with IPF underwent surgical lung
biopsy.31 Therefore, it is unlikely that their data
represented overall prognosis of IPF. In our study,
27 patients (31%) were clinically diagnosed as IPF
positive without surgical lung biopsy. All of them
fulfilled ATS diagnostic criteria of IPF. In addition,
those patients who did not show honeycombing on
HRCT, were excluded from our study to avoid the
inclusion of nonspecific interstitial pneumonia.22
Except for old age of patients diagnosed by ATS
diagnostic criteria, there was no difference in
clinical profile. The median survival of 88 patients
in our study was 46 months with 41% of five year
survival rate, which was not different from the
previous reports.9–14 It is interesting that Nagai et
al.29 reported the same five year survival rate in
234 Japanese patients with IPF.
IPF is a progressive and fatal lung disease
characterized by increasing parenchymal fibrosis
with time, leading to restrictive lung disease and
ultimately severe pulmonary hypertension.2–5 Oc-
casionally, an accelerated phase may occur at any
stage in the clinical course of the disease.32,33
Panos et al.19 reported that respiratory failure was
the cause of death in 39% of IPF, while cardiovas-
cular diseases in 27%, lung cancer in 10%, pulmon-
ary embolism in 3%, pulmonary infection in 3%, and
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cular diseases, such as heart failure and ischemic
heart disease, accounted for nearly one-third of
death in the patients with IPF. In the present
report, it can be observed that respiratory failure
was a more common cause of death, while only one
patient showed cardiovascular death. It may be
because cardiovascular disease is less common in
the people of Asia-Pacific region.21 This finding
strongly suggests that most of the Asian patients
with IPF might die of respiratory failure due to
progression of lung disease. In our study, the
difference in the death profile may be due to less
aggressive administration of corticosteroids as a
therapeutic trial, since this treatment can facil-
itate atherosclerosis. In IPF positive Japanese
patients, similar trend was observed.29 Progression
of IPF was the cause of death in 72% of patients,
followed by lung cancer in 13% and pulmonary
infection in 8%. We also found that in our patients,
acute exacerbation of IPF, defined by acute
progression of lung lesion within one month, with
obvious radiographic changes of rapidly progressive
consolidation and ground glass opacity, worsening
hypoxemia, and no evidence of infection, was the
more frequent presentation of respiratory failure
as a cause of death. It should be mentioned that
acute exacerbation of IPF might be overestimated
in this study as a cause of death because some
infections such as viral infections are not easily
detected by usual diagnostic methods. Among other
causes of death, pulmonary infection was the
frequent cause of death.
In conclusion, our study suggested the severity of
dyspnea and lung function tests at the time of
diagnosis as the predictive factors for the mortality
in IPF patients. Regarding treatment, specific
medical therapy showed no survival benefit in IPF
patients. On comparing with the reports from the
western countries, respiratory failure and pulmon-
ary infection were the more frequent causes of
death, while cardiovascular death was rare in
Korean patients with IPF.Acknowledgments
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